SI1007017T2 - Budezonid/formoterol formulacija za inhaliranje, ki ima nasipno gostoto od 0,30 g/ml do 0,36 g/ml, postopek za pripravo formulacije in njena uporaba - Google Patents

Budezonid/formoterol formulacija za inhaliranje, ki ima nasipno gostoto od 0,30 g/ml do 0,36 g/ml, postopek za pripravo formulacije in njena uporaba

Info

Publication number: SI1007017T2
Authority: SI; Slovenia
Prior art keywords: formulation; budesonide; inhalation; preparing; bulk density
Prior art date: 1997-01-20

Application number

SI9830754T

Other languages

English (en)

Slovenian (sl)

Other versions

SI1007017T1 (en

Inventor

Jan Trofast

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-20

Filing date

1998-01-13

Publication date

2011-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20405455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1007017(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-01-13 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-06-30 Publication of SI1007017T1 publication Critical patent/SI1007017T1/xx

2011-03-31 Publication of SI1007017T2 publication Critical patent/SI1007017T2/sl

Links

238000009472 formulation Methods 0.000 title 2
239000000203 mixture Substances 0.000 title 2
PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 title 1
229940080593 budesonide / formoterol Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SI9830754T 1997-01-20 1998-01-13 Budezonid/formoterol formulacija za inhaliranje, ki ima nasipno gostoto od 0,30 g/ml do 0,36 g/ml, postopek za pripravo formulacije in njena uporaba SI1007017T2 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9700135A SE9700135D0 (sv)	1997-01-20	1997-01-20	New formulation
PCT/SE1998/000040 WO1998031352A1 (fr)	1997-01-20	1998-01-13	Nouvelle formulation pour inhalation ayant une masse volumique apparente de 0,28 a 0,38 g/ml, procede de preparation et utilisation de cette formulation

Publications (2)

Publication Number	Publication Date
SI1007017T1 SI1007017T1 (en)	2005-06-30
SI1007017T2 true SI1007017T2 (sl)	2011-03-31

Family

ID=20405455

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9830754T SI1007017T2 (sl)	1997-01-20	1998-01-13	Budezonid/formoterol formulacija za inhaliranje, ki ima nasipno gostoto od 0,30 g/ml do 0,36 g/ml, postopek za pripravo formulacije in njena uporaba

Country Status (35)

Country	Link
US (2)	US6030604A (fr)
EP (1)	EP1007017B2 (fr)
JP (1)	JP2010059181A (fr)
KR (1)	KR100528416B1 (fr)
CN (1)	CN1271993C (fr)
AR (1)	AR011080A1 (fr)
AT (1)	ATE288260T1 (fr)
AU (1)	AU731192B2 (fr)
BR (1)	BR9811249A (fr)
CA (1)	CA2277913C (fr)
CZ (1)	CZ296301B6 (fr)
DE (1)	DE69828886T3 (fr)
DK (1)	DK1007017T4 (fr)
EE (1)	EE03951B1 (fr)
ES (1)	ES2235311T5 (fr)
HK (1)	HK1025515A1 (fr)
HU (1)	HU228622B1 (fr)
ID (1)	ID21865A (fr)
IL (1)	IL130838A (fr)
IS (1)	IS2788B (fr)
MY (1)	MY132999A (fr)
NO (1)	NO327426B1 (fr)
NZ (1)	NZ336594A (fr)
PL (1)	PL192115B1 (fr)
PT (1)	PT1007017E (fr)
RU (1)	RU2194497C2 (fr)
SA (1)	SA98180818B1 (fr)
SE (1)	SE9700135D0 (fr)
SI (1)	SI1007017T2 (fr)
SK (1)	SK283950B6 (fr)
TR (1)	TR199901690T2 (fr)
TW (1)	TW557217B (fr)
UA (1)	UA57764C2 (fr)
WO (1)	WO1998031352A1 (fr)
ZA (1)	ZA9878B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
US6503537B2 (en)	1997-03-20	2003-01-07	Schering Corporation	Preparation of powder agglomerates
US6495167B2 (en)	1997-03-20	2002-12-17	Schering Corporation	Preparation of powder agglomerates
SE9703407D0 (sv) *	1997-09-19	1997-09-19	Astra Ab	New use
SE9802073D0 (sv) *	1998-06-11	1998-06-11	Astra Ab	New use
GB9826284D0 (en)	1998-12-01	1999-01-20	Rhone Poulence Rorer Limited	Process
GB9826286D0 (en)	1998-12-01	1999-01-20	Rhone Poulence Rorer Limited	Process
WO2000035417A1 (fr) *	1998-12-11	2000-06-22	Pharmachemie B.V.	Preparation pharmaceutique pour inhalation d'un opioide
US8722668B2 (en) *	1998-12-23	2014-05-13	Daryl W. Hochman	Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
AR022695A1 (es) *	1999-01-28	2002-09-04	Schering Corp	PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US6623760B1 (en) *	1999-01-28	2003-09-23	Schering Corporation	Method of preparing particles for agglomeration
GB9903759D0 (en) *	1999-02-18	1999-04-14	Novartis Ag	Organic compounds
GB9904919D0 (en) *	1999-03-03	1999-04-28	Novartis Ag	Organic compounds
TWI277425B (en) *	1999-04-13	2007-04-01	Lilly Co Eli	Pulmonary administration of dry powder formulations for treating infertility
CA2273585A1 (fr)	1999-05-28	2000-11-28	Canpolar East Inc.	Capteurs servant a detecter les changements de temperature, le ph, les conditions chimiques, les conditions biologiques, les radiations, le champ electrique et la pression
CA2725731A1 (fr)	1999-06-05	2000-12-14	Innovata Biomed Limited	Dispositif d'administration
GB9920839D0 (en)	1999-09-04	1999-11-10	Innovata Biomed Ltd	Inhaler
DE19962926A1 (de) *	1999-12-24	2001-06-28	Bayer Ag	Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen
US6369115B1 (en) *	2000-03-20	2002-04-09	Dura Pharmaceuticals, Inc.	Stabilized powder formulations
AU2001252350A1 (en) *	2000-04-13	2001-10-30	Innovata Biomed Limited	Medicaments for treating respiratory disorders comprising formoterol and fluticasone
GB0012261D0 (en) *	2000-05-19	2000-07-12	Astrazeneca Ab	Novel process
GB0012260D0 (en)	2000-05-19	2000-07-12	Astrazeneca Ab	Novel composition
WO2002011711A2 (fr) *	2000-08-04	2002-02-14	Longwood Pharmaceutical Research, Inc.	Preparations de mometasone et bronchodilatateur pour administration par voie pulmonaire
FI20002177A0 (fi) *	2000-10-02	2000-10-02	Orion Yhtymae Oyj	Uusi yhdistelmä astman hoitoon
FI20002215A0 (fi) *	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit
FI20002216A0 (fi) *	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit astman hoitoon
BR0207062A (pt) *	2001-02-06	2004-10-05	Innovata Biomed Ltd	Composição farmacêutica bimodal, inalador para pó seco, método de aplicação de uma quantidade terapeuticamente eficaz de um ingrediente ativo substancialmente fino aos pulmões de um paciente, método de tratamento de um distúrbio respiratório, método de tratamento de doença pulmonar obstrutiva crÈnica (copd), uso de um agente antiinflamatório, uso de um broncodilatador, uso de uma mistura de um agente antiinflamatório e de um broncodilatador, e, processo para a fabricação de uma composição farmacêutica bimodal
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
TWI324934B (en) *	2001-08-28	2010-05-21	Schering Corp	Pharmaceutical compositions for the treatment of asthma
US7931022B2 (en)	2001-10-19	2011-04-26	Respirks, Inc.	Method and apparatus for dispensing inhalator medicament
JP2003221335A (ja)	2001-10-26	2003-08-05	Dey Lp	慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030203930A1 (en) *	2001-10-26	2003-10-30	Imtiaz Chaudry	Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) *	2001-10-26	2003-10-09	Imtiaz Chaudry	Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en)	2001-10-26	2004-03-09	Dey, L.P.	Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) *	2001-10-26	2003-07-31	Dey L.P.	Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
GB0128148D0 (en)	2001-11-23	2002-01-16	Innovata Biomed Ltd	Assembly
GB0208609D0 (en) *	2002-04-13	2002-05-22	Glaxo Group Ltd	Compositions
CN1652822A (zh) *	2002-05-07	2005-08-10	奥坦纳医药公司	用于治疗气道病症的可逆质子泵抑制剂和气道治疗剂的新组合
US20040023935A1 (en) *	2002-08-02	2004-02-05	Dey, L.P.	Inhalation compositions, methods of use thereof, and process for preparation of same
GB0219511D0 (en) *	2002-08-21	2002-10-02	Norton Healthcare Ltd	Method of preparing dry powder inhalation compositions
EA007377B1 (ru) *	2002-08-21	2006-10-27	Нортон Хелткэа Лтд.	Композиции для ингаляции
US20050158248A1 (en) *	2002-08-21	2005-07-21	Xian-Ming Zeng	Method of preparing dry powder inhalation compositions
GB0219512D0 (en) *	2002-08-21	2002-10-02	Norton Healthcare Ltd	Inhalation compositions with high drug ratios
KR20050056222A (ko) *	2002-09-30	2005-06-14	아쿠스피어 인코포레이티드	흡입용 지속 방출형 다공성 미세입자
US20040109826A1 (en) *	2002-12-06	2004-06-10	Dey, L.P.	Stabilized albuterol compositions and method of preparation thereof
RS51707B (sr) *	2002-12-12	2011-10-31	Nycomed Gmbh.	Kombinacija leka sastavljena od r, r - formoterola i ciklezonida
US6962006B2 (en) *	2002-12-19	2005-11-08	Acusphere, Inc.	Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) *	2002-12-19	2004-06-24	Acusphere, Inc.	Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1452179A1 (fr) *	2003-02-27	2004-09-01	CHIESI FARMACEUTICI S.p.A.	Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
US20040191176A1 (en) *	2003-03-28	2004-09-30	Kaplan Leonard W	Formulations for treatment of pulmonary disorders
US20060293293A1 (en) *	2003-05-22	2006-12-28	Altana Pharma Ag	Salmeterol and ciclesonide combination
SE527190C2 (sv) *	2003-06-19	2006-01-17	Microdrug Ag	Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE526509C2 (sv) *	2003-06-19	2005-09-27	Microdrug Ag	Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527200C2 (sv) *	2003-06-19	2006-01-17	Microdrug Ag	Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527189C2 (sv) *	2003-06-19	2006-01-17	Microdrug Ag	Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
SE526850C2 (sv) *	2003-06-19	2005-11-08	Microdrug Ag	Farmaceutisk kombinerad torr pulverdos separerade på gemensam dosbädd
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
GB0316335D0 (en) *	2003-07-11	2003-08-13	Glaxo Group Ltd	Pharmaceutical formulations
ES2362038T3 (es)	2003-09-02	2011-06-27	Norton Healthcare Limited	Procedimiento para preparar un medicamento.
PT1670482E (pt) *	2003-09-16	2014-03-12	Takeda Gmbh	Utilização de ciclesonida para o tratamento de doenças respiratórias
US20070020298A1 (en) *	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en)	2003-12-31	2007-01-25	Pipkin James D	Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
PL1708991T3 (pl) *	2004-01-22	2008-02-29	Pfizer	Pochodne sulfonoamidu do leczenia chorób
JO3102B1 (ar) *	2004-03-17	2017-09-20	Chiesi Framaceutici S P A	صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
PE20060159A1 (es) *	2004-03-24	2006-04-04	Chiesi Farma Spa	Monoclorhidrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-{[(1r)-2-(4-metoxifenil)-1-metiletil]amino}etil]-2-(1h)-quinolinona en forma cristalina y el proceso para su preparacion
EP1740188A1 (fr) *	2004-04-20	2007-01-10	Altana Pharma AG	Utilisation de ciclesonide pour le traitement des maladies respiratoires chez des patients fumeurs
WO2005102429A1 (fr)	2004-04-21	2005-11-03	Innovata Biomed Limited	Inhalateur
GB0409197D0 (en)	2004-04-24	2004-05-26	Innovata Biomed Ltd	Device
KR20070100735A (ko) *	2004-12-17	2007-10-11	씨아이피엘에이 엘티디.	약학적 화합물 및 조성물
CA2597557A1 (fr) *	2005-02-10	2006-08-17	Glaxo Group Limited	Procedes de fabrication du lactose au moyen de techniques de pre-classification et preparations pharmaceutiques ainsi obtenues
AU2006270165B2 (en)	2005-07-14	2010-03-11	Neothetics, Inc.	Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
CA2615378C (fr) *	2005-07-15	2015-02-17	Map Pharmaceuticals, Inc.	Multiples principes actifs pharmaceutiques combines dans des particules d'inhalation discretes et leurs formulations
WO2007009164A1 (fr) *	2005-07-15	2007-01-25	Eiffel Technologies Limited	Procede de formation de particules
JP2009519972A (ja) *	2005-12-15	2009-05-21	アキュスフィア，インコーポレイテッド	粒子ベースの経肺投与または経鼻投与用製薬の製造方法
CA2631492A1 (fr) *	2005-12-15	2007-06-21	Acusphere, Inc.	Procedes de preparation de formulations pharmaceutiques a base de particules destinees a une administration orale
US7913223B2 (en) *	2005-12-16	2011-03-22	Dialogic Corporation	Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
US20100119609A1 (en) *	2006-10-17	2010-05-13	John Daniel Dobak	Methods, compositions, and formulations for the treatment of thyroid eye disease
US8604080B2 (en)	2007-02-14	2013-12-10	W. Louis Cleveland	High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
ES2493641T3 (es) *	2007-06-28	2014-09-12	Cydex Pharmaceuticals, Inc.	Administración nasal de soluciones acuosas de corticosteroides
GB0714134D0 (en) *	2007-07-19	2007-08-29	Norton Healthcare Ltd	Dry-powder medicament
DE102007049931A1 (de)	2007-10-18	2009-04-23	Pharmatech Gmbh	Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
US20100120737A1 (en) *	2008-11-10	2010-05-13	Martin Feth	Amorphous ciclesonide
US20100291221A1 (en) *	2009-05-15	2010-11-18	Robert Owen Cook	Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9132084B2 (en) *	2009-05-27	2015-09-15	Neothetics, Inc.	Methods for administration and formulations for the treatment of regional adipose tissue
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
ES2774367T3 (es) *	2009-05-29	2020-07-20	Pearl Therapeutics Inc	Composiciones para el suministro respiratorio de agentes activos y métodos y sistemas asociados
EP2523667A4 (fr) *	2010-01-15	2014-04-02	Lithera Inc	Préparations pour gâteaux lyophilisés
US20110224229A1 (en)	2010-03-10	2011-09-15	Astrazeneca Ab	Novel Crystalline Form
AU2011315315B2 (en)	2010-10-12	2016-08-18	Cipla Limited	Pharmaceutical composition
CA2815374A1 (fr)	2010-11-24	2012-06-07	Lithera, Inc.	Formulations monotherapeutiques d'agonistes beta selectifs, lipophiles et a action prolongee, et procedes de traitement cosmetique de l'adiposite et du renflement de la silhouette
KR20150002774A (ko)	2012-04-11	2015-01-07	시플라 리미티드	아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
RU2510267C2 (ru) *	2012-06-15	2014-03-27	Шолекс Девелопмент Гмбх	Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
US20140275517A1 (en)	2013-03-15	2014-09-18	Pearl Therapeutics, Inc.	Methods and systems for conditioning of particulate crystalline materials
PL2821061T3 (pl)	2013-07-01	2018-05-30	Arven Ilac Sanayi Ve Ticaret A.S.	Nowe preparaty do inhalacji
US11344562B2 (en)	2017-08-15	2022-05-31	Nephron Pharmaceuticals Corporation	Aqueous nebulization composition
WO2020240350A1 (fr) *	2019-05-24	2020-12-03	Glenmark Pharmaceutical Limited	Composition de poudre inhalable à dose fixe comprenant du glycopyrronium, du formotérol et du propionate de fluticasone

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1429184A (en) *	1972-04-20	1976-03-24	Allen & Hanburys Ltd	Physically anti-inflammatory steroids for use in aerosols
US4161516A (en) †	1975-07-25	1979-07-17	Fisons Limited	Composition for treating airway disease
GB1571629A (en) *	1977-11-30	1980-07-16	Fisons Ltd	Pharmaceutical compositions containing beclomethasone dipropionate
CY1492A (en) *	1981-07-08	1990-02-16	Draco Ab	Powder inhalator
SE438261B (sv) *	1981-07-08	1985-04-15	Draco Ab	Anvendning i dosinhalator av ett perforerat membran
DE3268533D1 (en) *	1981-07-24	1986-02-27	Fisons Plc	Inhalation drugs, methods for their production and pharmaceutical formulations containing them
GB8825541D0 (en) †	1988-11-01	1988-12-07	Fisons Plc	Formulation
DE69027319T2 (de) *	1989-04-28	1996-11-21	Riker Laboratories Inc., Northridge, Calif.	Inhalationsvorrichtung für trockenpulver
US5176132A (en) *	1989-05-31	1993-01-05	Fisons Plc	Medicament inhalation device and formulation
DE59100388D1 (de) †	1990-01-29	1993-10-28	Ciba Geigy	Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers.
US5192548A (en) *	1990-04-30	1993-03-09	Riker Laboratoires, Inc.	Device
SE9100341D0 (sv) *	1991-02-04	1991-02-04	Astra Ab	Novel steroids
SE9100342D0 (sv) *	1991-02-04	1991-02-04	Astra Ab	Novel steroid esters
SE9101090D0 (sv) *	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
YU59092A (sh) *	1991-06-10	1994-12-28	Schering Corporation	Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
US5736124A (en) *	1991-12-12	1998-04-07	Glaxo Group Limited	Aerosol formulations containing P134a and particulate medicament
CA2123909C (fr) *	1991-12-18	2002-10-01	Christer Carl Gustav Carling	Nouvelle combinaison de formoterol et de budesonide
US5355872B1 (en) *	1992-03-04	1998-10-20	John H Riggs	Low flow rate nebulizer apparatus and method of nebulization
DE69332240T2 (de) †	1992-06-12	2003-04-10	Teijin Ltd., Osaka	Ultrafeines pulver zur inhalation und dessen herstellung
KR100291362B1 (ko) *	1992-10-16	2001-09-17	니뽄 신야쿠 가부시키가이샤	왁스매트릭스의제법
WO1995005147A1 (fr) *	1993-08-18	1995-02-23	Unilever Plc	Composition pour le rasage
BR9407686A (pt) †	1993-10-01	1997-02-04	Astra Ab	Processo e aparelho para o tratamento de um medicamento em pó finamente dividido uso do aparelho e aglomerados
IS1736B (is) *	1993-10-01	1999-12-30	Astra Ab	Aðferð og tæki sem stuðla að aukinni samloðun agna
GB9404945D0 (en) †	1994-03-15	1994-04-27	Glaxo Group Ltd	Pharmaceutical composition
US5647347A (en) *	1994-10-21	1997-07-15	Glaxo Wellcome Inc.	Medicament carrier for dry powder inhalator
US5503869A (en) *	1994-10-21	1996-04-02	Glaxo Wellcome Inc.	Process for forming medicament carrier for dry powder inhalator
US5654007A (en) *	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
SE9603669D0 (sv) *	1996-10-08	1996-10-08	Astra Ab	New combination
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation

1997
- 1997-01-20 SE SE9700135A patent/SE9700135D0/xx unknown
1998
- 1998-01-06 ZA ZA9878A patent/ZA9878B/xx unknown
- 1998-01-09 US US09/004,902 patent/US6030604A/en not_active Expired - Lifetime
- 1998-01-13 ID IDW990663A patent/ID21865A/id unknown
- 1998-01-13 WO PCT/SE1998/000040 patent/WO1998031352A1/fr active IP Right Grant
- 1998-01-13 DK DK98901618.3T patent/DK1007017T4/da active
- 1998-01-13 PL PL334527A patent/PL192115B1/pl unknown
- 1998-01-13 ES ES98901618T patent/ES2235311T5/es not_active Expired - Lifetime
- 1998-01-13 CZ CZ0255799A patent/CZ296301B6/cs not_active IP Right Cessation
- 1998-01-13 AU AU57859/98A patent/AU731192B2/en not_active Expired
- 1998-01-13 AT AT98901618T patent/ATE288260T1/de active
- 1998-01-13 TR TR1999/01690T patent/TR199901690T2/xx unknown
- 1998-01-13 PT PT98901618T patent/PT1007017E/pt unknown
- 1998-01-13 UA UA99074044A patent/UA57764C2/uk unknown
- 1998-01-13 NZ NZ336594A patent/NZ336594A/xx not_active IP Right Cessation
- 1998-01-13 SK SK959-99A patent/SK283950B6/sk not_active IP Right Cessation
- 1998-01-13 HU HU0000714A patent/HU228622B1/hu unknown
- 1998-01-13 CA CA002277913A patent/CA2277913C/fr not_active Expired - Lifetime
- 1998-01-13 KR KR10-1999-7006414A patent/KR100528416B1/ko not_active Expired - Lifetime
- 1998-01-13 RU RU99118587/14A patent/RU2194497C2/ru active
- 1998-01-13 EE EEP199900295A patent/EE03951B1/xx unknown
- 1998-01-13 IL IL13083898A patent/IL130838A/xx not_active IP Right Cessation
- 1998-01-13 EP EP98901618A patent/EP1007017B2/fr not_active Expired - Lifetime
- 1998-01-13 CN CNB988019000A patent/CN1271993C/zh not_active Expired - Lifetime
- 1998-01-13 DE DE69828886T patent/DE69828886T3/de not_active Expired - Lifetime
- 1998-01-13 BR BR9811249-0A patent/BR9811249A/pt not_active Application Discontinuation
- 1998-01-13 SI SI9830754T patent/SI1007017T2/sl unknown
- 1998-01-15 MY MYPI98000164A patent/MY132999A/en unknown
- 1998-01-19 AR ARP980100224A patent/AR011080A1/es not_active Application Discontinuation
- 1998-02-10 SA SA98180818A patent/SA98180818B1/ar unknown
- 1998-03-11 TW TW087103589A patent/TW557217B/zh not_active IP Right Cessation
1999
- 1999-07-06 IS IS5108A patent/IS2788B/is unknown
- 1999-07-19 NO NO19993539A patent/NO327426B1/no not_active IP Right Cessation
- 1999-11-02 US US09/431,916 patent/US6287540B1/en not_active Expired - Lifetime
2000
- 2000-08-01 HK HK00104814A patent/HK1025515A1/xx not_active IP Right Cessation
2009
- 2009-11-06 JP JP2009255070A patent/JP2010059181A/ja active Pending

Also Published As

Publication number	Publication date
CN1271993C (zh)	2006-08-30
IS5108A (is)	1999-07-06
KR100528416B1 (ko)	2005-11-16
BR9811249A (pt)	2000-09-05
SK95999A3 (en)	2000-01-18
SI1007017T1 (en)	2005-06-30
HU228622B1 (en)	2013-04-29
TW557217B (en)	2003-10-11
NZ336594A (en)	2001-01-26
EE03951B1 (et)	2003-02-17
JP2010059181A (ja)	2010-03-18
DK1007017T4 (da)	2011-02-28
WO1998031352A1 (fr)	1998-07-23
EP1007017B1 (fr)	2005-02-02
PT1007017E (pt)	2005-05-31
CZ255799A3 (cs)	1999-10-13
AU731192B2 (en)	2001-03-29
CN1243436A (zh)	2000-02-02
SA98180818B1 (ar)	2006-03-25
UA57764C2 (uk)	2003-07-15
DE69828886D1 (de)	2005-03-10
HUP0000714A2 (hu)	2000-08-28
JP4512204B2 (ja)	2010-07-28
MY132999A (en)	2007-10-31
ES2235311T5 (es)	2011-03-31
CA2277913C (fr)	2007-03-06
CA2277913A1 (fr)	1998-07-23
DE69828886T3 (de)	2011-06-01
PL334527A1 (en)	2000-02-28
RU2194497C2 (ru)	2002-12-20
CZ296301B6 (cs)	2006-02-15
HK1025515A1 (en)	2000-11-17
AR011080A1 (es)	2000-08-02
IL130838A0 (en)	2001-01-28
EP1007017A1 (fr)	2000-06-14
US6287540B1 (en)	2001-09-11
IL130838A (en)	2005-07-25
NO327426B1 (no)	2009-06-29
JP2001508793A (ja)	2001-07-03
ES2235311T8 (es)	2011-05-13
SK283950B6 (sk)	2004-05-04
US6030604A (en)	2000-02-29
NO993539D0 (no)	1999-07-19
NO993539L (no)	1999-09-20
ZA9878B (en)	1998-07-20
TR199901690T2 (xx)	1999-09-21
ATE288260T1 (de)	2005-02-15
KR20000070188A (ko)	2000-11-25
ES2235311T3 (es)	2005-07-01
ID21865A (id)	1999-08-05
EE9900295A (et)	2000-02-15
IS2788B (is)	2012-06-15
SE9700135D0 (sv)	1997-01-20
DK1007017T3 (da)	2005-05-02
AU5785998A (en)	1998-08-07
HUP0000714A3 (en)	2000-10-30
DE69828886T2 (de)	2006-04-06
EP1007017B2 (fr)	2010-12-08
PL192115B1 (pl)	2006-08-31

Publication	Publication Date	Title
SI1007017T2 (sl)	2011-03-31	Budezonid/formoterol formulacija za inhaliranje, ki ima nasipno gostoto od 0,30 g/ml do 0,36 g/ml, postopek za pripravo formulacije in njena uporaba
HUP0000841A3 (en)	2001-01-29	New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising budesonide and process for its preparation
HUP0000843A3 (en)	2000-10-30	New formulation for inhalation having a poured bulnew formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising fok density of from 0,28 to 0,38 g/ml, comprising formoterol rmoterol
IL116505A0 (en)	1996-03-31	Compounds with progesterone-antagonistic and antiestrogenic action and the use thereof for the manufacture of pharmaceutical agents
HUP0000755A3 (en)	2001-03-28	New formulation for inhalation having a poured bulk density of from 0,28 to 0,38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof
HUP0203611A3 (en)	2004-07-28	14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
SI1009394T1 (en)	2004-04-30	New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising formoterol
GR3019681T3 (en)	1996-07-31	3- and 5-substituted 1,2,3,4-oxatriazole-5-imine compounds, a process for the preparation thereof, a pharmaceutical preparation containing said compounds and the use of said compounds for the preparation of medicaments.
IL162864A (en)	2005-03-20	Formulation for inhalation having a poured bulk density of from 0.28 to 0.38g/ml, comprising formoterol
SG33434A1 (en)	1996-10-18	Pharmaceutical preparation containing estra-1,3,5(10)-triene-derivatives